Abstract
Hepatocyte growth factor (HGF) has shown promise in treating patients with critical limb ischemia (CLI). We performed this phase II study to assess the safety and efficacy of the intramuscular (IM) injection of VM202, plasmid DNA expressing 2 isoforms of HGF, in CLI patients. We enrolled 52
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have